SHANGHAI, May 22, 2026 —— The 10th VBEF Future Healthcare Summit successfully concluded in Shanghai from May 19 to 21, 2026. Bringing together industry leaders, top-tier investment institutions, and innovative enterprises, the summit served as a pivotal platform to discuss industrial transformation, capital opportunities, and the future development trajectory of the healthcare sector.
Glenn Hou , Founding Partner of CIC, attended the summit and moderated the Investment Roundtable, facilitating in-depth dialogues with industry elites to foster consensus for the high-quality development of China’s healthcare and pharmaceutical industry.
Leveraging his profound industry consulting expertise and capital insights, Glenn Hou led the panel discussion under the theme Patient Capital for Long-Term Growth, Steady Value Creation in Healthcare. The session focused on in-depth explorations of industry investment trends, enterprise growth pathways, capital empowerment, global expansion strategies, and high-value sector discovery.
Panel guests included Chen Mo, Head of Biotech & Healthcare at Shenzhen Angel FOF; Li Chen, Co-President of Shanghai Biotech M&A Fund; Xiao Zhi, Deputy General Manager of SDIC Innovation; and Zheng Yubo, General Manager of Guosheng Capital. Drawing on their frontline operational experience, the guests shared cutting-edge industry insights, conducted an in-depth analysis of industrial pain points, and explored pathways for industrial breakthroughs, delivering pragmatic and actionable strategies for the attendees.
Key Takeaways from the Roundtable
• State-owned patient capital upholds the principle of long-termism, with a deepened focus on the healthcare sector, prioritizing strategic positioning and in-depth industrial empowerment.
• Distinct regional investment patterns have emerged: the Yangtze River Delta focuses on industrial M&A and integration; the Greater Bay Area accelerates early-stage innovation incubation; western regions nurture high-quality projects through industrial parks; and national-level capital coordinates cross-regional industrial layouts.
• Moving forward, state-owned capital will continue to act as a market stabilizer, staying rooted in technological innovation and value investing to support the steady growth of China’s healthcare industry.
As a seasoned IPO Consultant, CIC has rich experience in enabling landmark IPOs for life sciences enterprises in global capital markets, including Haixi Pharmaceutical[2] (02637.HK), Star Sports Medicine[3] (01609.HK), Xuanzhu Biopharmaceutial[4] (02575.HK), Pegbio[5] (02565.HK), Taimei Medical Tchnology[6] (02576.HK), HighTide Therapeutics[7] (02511.HK), Jiuyuan Gene Engineering[8] (02566.HK), and Fangzhou[9] (06086.HK).
CIC has also published a series of reports, including the GLP-1 Industry Bluebook, Oral Insulin Industry Bluebook, and Global and China Hyperphosphatemia Drug Industry Bluebook. These forward-looking, data-driven insights identified core competitive advantages of enterprises and accurately forecast industry trends.
Going forward, CIC will leverage our professional expertise and core resources, and further develop our industry research and consulting capacities, aiming to empower life sciences enterprises in their innovation and growth journeys, and global expansion.
About the VBEF Future Healthcare Summit
Hosted by VCBeat Health , the VBEF Future Healthcare Summit is a flagship industry event focused on innovative assets in the life sciences and healthcare sector. The 10th edition of the summit centered on the theme of China Assets, building a bridge between innovative enterprises and global capital. Covering cutting-edge tracks across pharmaceuticals, medical devices, and digital health, the summit integrates policy interpretation, industrial cooperation, and capital matching, fostering the high-quality and collaborative development of the healthcare ecosystem.
About CIC
CIC is a professional consulting firm offering tailored end-to-end support across the full investment and financing lifecycle. The firm boasts a world-leading track record in guiding landmark first-in-sector IPOs across global markets, alongside unrivaled reach and in-depth coverage capabilities across specialized niche market segments.
CIC helps enterprises refine scalable business models and craft compelling capital narratives to enable seamless access to global capital markets, while serving as a trusted due diligence partner to investment institutions. It delivers granular industry insights and direct access to subject matter experts, empowering clients to identify high-value opportunities and mitigate critical risks effectively.
Media Contact
